We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+6.76%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$50M
(+18%)
Cap. Flow
+$37M
Cap. Flow
% of AUM
11.45%
Top 10 Holdings %
Top 10 Hldgs %
80.32%
Holding
49
New
10
Increased
8
Reduced
14
Closed
15
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$7.06M |
| 2 |
Abbott
ABT
|
+$4.8M |
| 3 |
McKesson
MCK
|
+$4.23M |
| 4 |
Becton Dickinson
BDX
|
+$3.81M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$3.65M |
Top Sells
| 1 |
Amgen
AMGN
|
+$7.25M |
| 2 |
DocGo
DCGO
|
+$4.17M |
| 3 |
Viatris
VTRS
|
+$2.39M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$2.14M |
| 5 |
RadNet
RDNT
|
+$2.08M |
Sector Composition
| 1 | Healthcare | 40.41% |
| 2 | Consumer Staples | 0.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$782B
| $175M | 54.16% |
400,000
+300,000
| +300% | +$126M |
|
2
CALL
iShares 20+ Year Treasury Bond ETF
TLT
$41.9B
| $15.4M | 4.77% |
+150,000
| New | +$15.6M |
|
|
3
Viatris
VTRS
$20.2B
| $12.5M | 3.86% |
1,250,000
-250,000
| -17% | -$2.39M |
|
|
MDRX
4
DELISTED
Veradigm Inc. Common Stock
MDRX
| $11.7M | 3.62% |
930,000
-20,000
| -2% | -$243K |
|
5
Phreesia
PHR
$673M
| $8.99M | 2.78% |
290,000
-30,000
| -9% | -$939K |
|
6
Collegium Pharmaceutical
COLL
$1.18B
| $8.06M | 2.49% |
375,000
+20,000
| +6% | +$454K |
|
7
Tenet Healthcare
THC
$17.2B
| $7.73M | 2.39% |
95,000
-5,000
| -5% | -$356K |
|
8
Tactile Systems Technology
TCMD
$663M
| $7.48M | 2.31% |
300,000
-60,000
| -17% | -$1.25M |
|
|
9
BioMarin Pharmaceuticals
BMRN
$11.6B
| $6.5M | 2.01% |
+75,000
| New | +$7.06M |
|
|
STRM
10
DELISTED
Streamline Health Solutions
STRM
| $6.26M | 1.94% |
328,725
| – | – |
|
|
11
McKesson
MCK
$98.5B
| $5.98M | 1.85% |
14,000
+11,000
| +367% | +$4.23M |
|
12
SI-BONE Inc
SIBN
$786M
| $5.4M | 1.67% |
200,000
-75,000
| -27% | -$1.83M |
|
13
Sanofi
SNY
$106B
| $5.12M | 1.58% |
95,000
| – | – |
|
|
14
Abbott
ABT
$172B
| $4.91M | 1.52% |
+45,000
| New | +$4.8M |
|
15
AngioDynamics
ANGO
$584M
| $4.85M | 1.5% |
465,000
-10,000
| -2% | -$96.2K |
|
|
16
RadNet
RDNT
$4.95B
| $4.57M | 1.41% |
140,000
-71,500
| -34% | -$2.08M |
|
17
Cerus
CERS
$643M
| $4.3M | 1.33% |
1,750,000
-500,000
| -22% | -$1.19M |
|
18
AtriCure
ATRC
$1.8B
| $4.2M | 1.3% |
85,000
+44,624
| +111% | +$2.06M |
|
|
19
Becton Dickinson
BDX
$44.1B
| $3.96M | 1.22% |
+15,000
| New | +$3.81M |
|
|
20
Teva Pharmaceuticals
TEVA
$37.5B
| $3.39M | 1.05% |
+450,000
| New | +$3.65M |
|
21
Alkermes
ALKS
$8.66B
| $3.13M | 0.97% |
100,000
+25,000
| +33% | +$757K |
|
22
InMode
INMD
$897M
| $2.8M | 0.87% |
75,000
-40,000
| -35% | -$1.4M |
|
23
Ironwood Pharmaceuticals
IRWD
$637M
| $2.39M | 0.74% |
225,000
+15,000
| +7% | +$161K |
|
24
DexCom
DXCM
$30.1B
| $2.06M | 0.64% |
+16,000
| New | +$1.94M |
|
25
Rigel Pharmaceuticals
RIGL
$771M
| $1.61M | 0.5% |
125,000
-75,000
| -38% | -$1.01M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU